COX-2 Inhibitor/Aspirin GI Safety Study Suggested By FDA Advisory Cmte.
Executive Summary
Additional research is needed on the gastrointestinal safety of concomitant COX-2 inhibitor and aspirin use, FDA's Arthritis Advisory Committee recommended during its Feb. 7-8 review of sNDAs for Pharmacia/Pfizer's Celebrex and Merck's Vioxx.
You may also be interested in...
Novartis COX-189 TARGET Study Will Assess CV Safety Of COX-2 Inhibitor
Novartis' long-term COX-2 inhibitor safety study will be sufficiently large to provide "clear" evidence of the cardiovascular safety of COX-189, Clinical R&D Head James Shannon told analysts in New York City Oct. 30
Novartis COX-189 TARGET Study Will Assess CV Safety Of COX-2 Inhibitor
Novartis' long-term COX-2 inhibitor safety study will be sufficiently large to provide "clear" evidence of the cardiovascular safety of COX-189, Clinical R&D Head James Shannon told analysts in New York City Oct. 30
Celebrex, Vioxx GI Safety Differences May Be Indistinguishable - FDA Cmte.
Gastrointestinal safety outcome differences between Pharmacia/Pfizer's Celebrex and Merck's Vioxx may be a factor of statistical "technicalities," FDA Arthritis Advisory Committee voting consultant David Wofsy, MD, University of California-San Francisco, suggested.